	Legislative Proposal 2022-A ~ CDS Schedule Update Draft #1	
1	HLS/SLS 22-	
2	Regular Session, 2022	
3	House/Senate Bill No.	
4	By Representative/Senator	
5		
6	CONTROLLED SUBSTANCES: Adds multiple substances to Schedule I, and	
7	Serdexmethylphenidate in Schedule IV.	
8		
9	AN ACT	
10		
11	To amend and reenact R.S. 40:964, relative to the composition of various schedules of control	lled
12	substances.	
13	Be it enacted by the Legislature of Louisiana:	
14	Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:	
15	§964. Composition of schedules	
16	* * *	
17	Schedule I	
18	A. Opiates.	
19	Unless specifically excepted or unless listed in another schedule, any of th	e
20	following opiates, including their isomers, esters, ethers, salts, or salts of	
21	isomers, esters, and ethers, whenever the existence of such isomers, esters,	,
22	ethers, or salts is possible within the specific chemical designation:	
23	(1) – (79)	
24	(80) Phenylfentanyl	

	Legislative Proposal 2022-A ~ CDS Schedule Update Draft #1
25	(81) para-methylfentanyl
26	(82) Thiofuranylfentanyl
27	(83) beta-methylfentanyl
28	(84) beta-phenylfentanyl
29	(85) 2-fluoro-orthofluorofentanyl
30	(86) 4-methylacetylfentanyl
31	(87) Orthofluorobutyrylfentanyl
32	(88) Orthomethylacetylfentanyl
33	(89) Orthomethylmethoxyacetylfentanyl
34	(90) Orthofluoroacrylfentanyl
35	(91) Fentanyl carbamate
36	(92) Orthofluoroisobutyrylfentanyl
37	(93) para-fluorofuranylfentanyl
38	(94) Isotonitazene (N,N-diethyl-2-[(4-isopropoxyphenyl)methyl]-5-nitro-
39	<u>1H-benzimidazole-1-ethanamine)</u>
40	(95) Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-
41	<u>benzimidazole-1-ethanamine)</u>
42	(96) Butonitazene (N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1H-
43	<u>benzimidazole-1-ethanamine)</u>
44	(97) Flunitazene (N,N-diethyl-2-(4-fluorophenyl)methyl]-5-nitro-1H-
45	<u>benzimidazole-1-ethanamine)</u>
46	(98) Protonitazene (N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-
47	benzimidazole-1-ethanamine)

	egislative Proposal 2022-A ~ CDS Schedule Update Draft #1			
48	(99) N-pyrrolidino etonitazene (2-[(4-ethoxyphenyl)methyl]-5-nitro-1-	2-		
49	(pyrrolidino-1-yl)ethyl]-1H-benzimidazole)			
50	(100) Etodesnitazene (N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-1H-			
51	benzimidazole-1-ethanamine)			
52	(101) Metodesnitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-1H-			
53	benzimidazole-1-ethanamine)			
54	* * *			
55	C. Hallucinogenic Substances			
56	Unless specifically excepted or unless listed in another schedule, any ma	terial,		
57	compound, mixture, or preparation, which contains any quantity of the			
58	following hallucinogenic substances, or which contains any of their salts	,		
59	isomers, or salts of isomers, whenever the existence of such salts, isomer	s, or		
60	salts of isomers is possible within the specific chemical designation; for			
61	purposes of this Paragraph only, the term "isomer" includes the optical,			
62	position, and geometric isomers:			
63	(1) – (65)			
64	(66) para-methoxymethamphetamine (PMMA)			
65	* * *			
66	E. Stimulants			
67	Unless specifically excepted, or contained within a pharmaceutical produ	ct		
68	approved by the United States Federal Food and Drug Administration, or			
69	unless listed in another schedule, any material, compound, mixture, or			
70	preparation which contains any quantity of the following substances having	ng a		
71	stimulant effect on the central nervous system, including its salts, isomers	,		

72	esters, or ethers and salts of isomers, esters, or ethers whenever the existence
73	of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is
74	possible within the specific chemical designation:
75	$(1) - (11) \dots$
76	(12) 4,4-dimethylaminorex (4,4-DMAR)
77	F. Synthetic Cannabinoids
78	Unless specifically excepted, or contained within a pharmaceutical product
79	approved by the United States Food and Drug Administration, or unless listed
80	in another schedule, any material, compound, mixture, or preparation which
81	contains any quantity of a synthetic cannabinoid found to be in any of the
82	following individual compounds or chemical groups, or any of those
83	individual compounds or groups which contain any synthetic cannabinoid
84	salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the
85	existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic
86	analogs is possible within the specific compounds or chemical groups:
87	$(1) - (28) \dots$
88	(29) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-B]pyridine-
89	<u>3-carboxamide [5FCUMYL-P7AICA]</u>
90	(30) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
91	[CBL2201]
92	(31) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-
93	3-carboxamide [5F-AB-PINACA]
94	(32) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
95	[4-CN-CUMYL-BUTINACA]

	Legislative Proposal 2022-A ~ CDS Schedule Update	Draft #1
96	(33) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxami	do)-3-methyl-
97	butanoate [MMB-CHMICA; AMB-CHMICA]	
98	(34) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one	
99	[N-ethylpentylone; ephylone]	
100	* * *	
101	Schedule IV	
102	* * * *	
103	D. Stimulants	
104	Unless specifically excepted or unless listed in another schedul	e, any material,
105	compound, mixture, or preparation which contains any quantit	y of the
106	following substances, including its salts, isomers, and salts of i	somers:
107	(1) – (14)	
108	(15) Serdexmethylphenidate	
109	* * *	
110	Section 2. The Louisiana State Law Institute is hereby authorized and dire	ected to
111	alphabetize the entries in the Opiates, Hallucinogenic Substances, and Stin	nulants sections
112	of Schedule I and the Stimulants section of Schedule IV.	
113	[END]	